ArticleDialogues in clinical neuroscience2004
Postmortem studies in Parkinson's disease.
Article in Dialogues in clinical neuroscience, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Actual Data on Essential Trace Elements in Parkinson's Disease.Nutrients · 2025Pooled it
- Alpha-synuclein and mitochondrial permeability transition pore interactions in rotenone-induced Parkinson's disease models: neuroprotective promise of cyclosporine A.Biochemistry and biophysics reports · 2026Article
- Nigrostriatal dopaminergic vulnerability in Parkinson's disease: Neuroprotective strategies.Neural regeneration research · 2026Article
- In vivo and in vitro perspectives in Parkinson's disease: Mechanisms and the role of phytomedicine.Journal of food and drug analysis · 2025Review
- Genetically encoded and modular subcellular organelle probes reveal dysfunction in lysosomes and mitochondria driven by PRKN knockout.iScience · 2025Article
- Physical activity affects DNA methylation-derived inflammation markers in a community-based Parkinson's disease study.Brain, behavior, & immunity - health · 2025Article
- Genotype-Based Housing as a Potential Confounder in Studies Using Transgenic Mouse Models-Insight from the A53T Mouse Model of Parkinson's Disease.Biomedicines · 2025Article
- A Theoretical and Practical Analysis of Membrane Protein Genes Altered in Neutrophils in Parkinson's Disease.Current issues in molecular biology · 2025Article
- Genetically Encoded and Modular SubCellular Organelle Probes (GEM-SCOPe) reveal lysosomal and mitochondrial dysfunction driven bybioRxiv : the preprint server for biology · 2025Article
- Review
- Metformin improves cognitive dysfunction through SIRT1/NLRP3 pathway-mediated neuroinflammation in db/db mice.Journal of molecular medicine (Berlin, Germany) · 2024Article
- Integration of iPSC-Derived Microglia into Brain Organoids for Neurological Research.International journal of molecular sciences · 2024Review
- Silencing Parkinson's risk allele Rit2 sex-specifically compromises motor function and dopamine neuron viability.NPJ Parkinson's disease · 2024Article
- Unravelling the Parkinson's puzzle, from medications and surgery to stem cells and genes: a comprehensive review of current and future management strategies.Experimental brain research · 2024Review
- Acupuncture influences multiple diseases by regulating gut microbiota.Frontiers in cellular and infection microbiology · 2024Review
- CRISPR/sgRNA-directed synergistic activation mediator (SAM) as a therapeutic tool for Parkinson´s disease.Gene therapy · 2024Article
- Rit2 silencing in dopamine neurons drives a Parkinsonian phenotype.bioRxiv : the preprint server for biology · 2023Article
- Impaired dopamine release in Parkinson's disease.Brain : a journal of neurology · 2023Review
- Advanced human iPSC-based preclinical model for Parkinson's disease with optogenetic alpha-synuclein aggregation.Cell stem cell · 2023Article
- Effects of Flavonoids on Cancer, Cardiovascular and Neurodegenerative Diseases: Role of NF-κB Signaling Pathway.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
No animal model to date perfectly replicates Parkinson's disease (PD) etiopathogenesis, and the anatomical organization of the nigrostriatal system differs considerably between species. Human postmortem material therefore remains the gold standard for both formulating hypotheses for subsequent testing in in vitro and in vivo PD models and verifying hypotheses derived from experimental PD models with regard to their validity in the human disease. This article focuses on recent and relevant fields in which human postmortem work has generated significant impact in our understanding of PD. These fields include Lewy body formation, regional vulnerability of dopaminergic neurons, oxidative/nitrative cellular stress, inflammation, apoptosis, infectious and environmental agents, and nondopaminergic lesions.
Indexed as
Identifiers
22033507PMC3181805W2100398073What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.